NAD+ vs NMN vs NR: What the Precursor Research Compares

A common question in the NAD+ research literature is how the three principal forms — NAD+ itself, nicotinamide mononucleotide (NMN), and nicotinamide riboside (NR) — relate to one another and how researchers differentiate them in studies. Here is what the published literature describes, framed as laboratory and pharmacokinetic observations rather than clinical guidance.

Structural and metabolic relationships

NAD+ cannot cross most cell membranes intact at physiological scale. NMN and NR are biosynthetic precursors that cells take up and convert into NAD+ intracellularly via distinct transporter and enzymatic mechanisms [1].

• NAD+ is the active coenzyme form. In cell-based assays it is used directly; its utility as an exogenously administered precursor in organisms is limited by membrane permeability.
• NMN (nicotinamide mononucleotide) is a mononucleotide one step upstream of NAD+ in the salvage pathway. In mouse studies it is the most commonly used pharmacological tool to raise NAD+ levels acutely.
• NR (nicotinamide riboside) is a nucleoside two steps upstream of NAD+. It was characterized as uniquely and orally bioavailable in both mice and humans in a 2016 pharmacokinetic study — one of the first to trace NR's conversion to NAD+ metabolites in human blood following oral dosing [2].

The key distinction that reviews emphasize: NR and NMN do not directly raise cellular NAD+ but rather raise the pool of metabolites used to synthesize NAD+ via salvage-pathway enzymes [3].

What the pharmacokinetic literature reports

NR in humans. The landmark 2016 study (Trammell et al., *Nature Communications*) demonstrated dose-dependent increases in NAD+ metabolites in human blood following single oral doses of NR at 100, 300, and 1,000 mg. A subsequent study in healthy elderly men supplemented with 1,000 mg NR daily for 21 days reported increases in NAD+ and NMN in blood, and corresponding increases in NAD+ metabolites in muscle [2].

NMN in humans. Human safety and pharmacokinetic studies of NMN began publishing in the early 2020s. A randomized, multicenter, double-blind, placebo-controlled trial in healthy middle-aged adults evaluated NMN across a range of doses and reported it was generally well-tolerated and associated with dose-dependent increases in blood NAD+ metabolites [4]. A review of human clinical trials as of 2023 characterized NMN as safe in all disclosed trials while noting that results on age-related physiological endpoints were mixed [5].

Head-to-head comparisons. Direct, prospective comparisons of NMN vs NR in the same human population are limited. A 2021 precursor-comparison review examined published pharmacokinetic data across studies and discussed structural and enzymatic differences in how each compound enters the salvage pathway [6]. A more recent pilot study compared intravenous NAD+ and NR tolerability in a real-world clinical setting, noting distinct tolerability profiles [7]. These are early-stage observations; the field has not established which precursor is superior for any given research application.

What the literature does NOT establish

Reviewers are explicit on several points worth noting:

• Studies in animal models generally use doses that are not directly comparable to doses studied in humans.
• Most human trials have been short (4–12 weeks), small (tens of participants), and focused on safety/pharmacokinetics — not on clinical outcomes.
• A 2021 review specifically characterized the evidence for human benefit from NAD+ precursor supplementation as requiring much longer and larger studies before any conclusions can be drawn [3].
• A meta-analysis of NAD+ precursor trials found mixed metabolic results, including some signals (e.g., on lipid fractions) in specific patient populations, while noting null effects in healthy individuals [8].

How researchers choose between forms

In pre-clinical laboratory work, the choice between NAD+, NMN, and NR typically depends on the experimental system: NAD+ for in-vitro enzymatic assays, NMN or NR for animal-model studies where oral or injectable administration is required. The structural differences (and the distinct transporter biology) make each compound a slightly different research tool rather than interchangeable entities.

For the broader context, see the [NAD+ research overview](/research/nad-plus).